NOXXON Pharma N.V.: Half-yearly Report on the Liquidity Contract with Invest Securities
13 Juillet 2020 - 6:00PM
Business Wire
Regulatory News:
NOXXON Pharma N.V. (Paris:ALNOX) (Euronext
Growth Par is: ALNOX), a biotechnology company focused on
improving cancer treatments by targeting the tumor microenvironment
(TME), announced today that, pursuant to the liquidity contract
entrusted to Invest Securities by NOXXON Pharma N.V., the following
assets appeared on the liquidity account:
As of June 30, 2020:
- Number of shares: 52,781
- Cash balance of the liquidity account: € 17,123.60
For the period January 1, 2020 – June 30, 2020:
- Total number of shares bought: 203,700 representing an amount
of: € 111,501.31 representing total transactions of: 70
- Total number of shares sold: 165,459 representing an amount of:
€ 97,505.76 representing total transactions of: 55
As a reminder, as of December 31, 2019, the following assets
appeared in the liquidity account:
- Number of shares: 14,540
- Cash balance of the liquidity account: € 31,119.15
For more detailed information please see the annex of this press
release.
About NOXXON
NOXXON’s oncology-focused pipeline acts on the tumor
microenvironment (TME) and the cancer immunity cycle by breaking
the tumor protection barrier and blocking tumor repair. By
neutralizing chemokines in the tumor microenvironment, NOXXON’s
approach works in combination with other forms of treatment to
weaken tumor defenses against the immune system and enable greater
therapeutic impact. Building on extensive clinical experience and
safety data, the lead program NOX-A12 has delivered top-line data
from a Keytruda® combination trial in metastatic colorectal and
pancreatic cancer patients and further studies are being planned in
these indications. In September 2019 the company initiated an
additional trial with NOX-A12 in brain cancer in combination with
radiotherapy. The combination of NOX-A12 and radiotherapy has been
granted orphan drug status in the US and EU for the treatment of
certain brain cancers. The company’s second clinical-stage asset
NOX-E36 is a Phase 2 TME asset targeting the innate immune system.
NOXXON plans to test NOX‑E36 in patients with solid tumors both as
a monotherapy and in combination. Further information can be found
at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme
Corp
https://www.linkedin.com/company/noxxon-pharma-ag
https://twitter.com/noxxon_pharma
Disclaimer
Certain statements in this communication contain formulations or
terms referring to the future or future developments, as well as
negations of such formulations or terms, or similar terminology.
These are described as forward-looking statements. In addition, all
information in this communication regarding planned or future
results of business segments, financial indicators, developments of
the financial situation or other financial or statistical data
contains such forward-looking statements. The company cautions
prospective investors not to rely on such forward-looking
statements as certain prognoses of actual future events and
developments. The company is neither responsible nor liable for
updating such information, which only represents the state of
affairs on the day of publication.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200713005425/en/
For more information, please contact: NOXXON Pharma
N.V. Aram Mangasarian, Ph.D., Chief Executive Officer Tel. +49
(0) 30 726247 0 amangasarian@noxxon.com
Trophic Communications Gretchen Schweitzer or Joanne
Tudorica Tel. +49 (0) 89 2388 7730 or +49 (0) 176 2103 7191
schweitzer@trophic.eu
NewCap Arthur Rouillé Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr